N6-Methyladenosine Methylation Regulator Fto Promotes Oxidative Stress and Induces Cell Apoptosis in Ovarian Cancer

References

• Kuroki L , GuntupalliSR. Treatment of epithelial ovarian cancer. BMJ371, m3773 (2020).
   PubMedGoogle Scholar
• Menon U , Gentry-MaharajA , BurnellMet al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet397(10290), 2182–2193 (2021).
   PubMed Web of Science ®Google Scholar
• Xu J , BiG , LuoQet al. PHLDA1 modulates the endoplasmic reticulum stress response and is required for resistance to oxidative stress-induced cell death in human ovarian cancer cells. J. Cancer12(18), 5486–5493 (2021).
   PubMed Web of Science ®Google Scholar
• Chen X , ZhaoY , LuoWet al. Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells. Theranostics10(22), 10290–10308 (2020).
   PubMed Web of Science ®Google Scholar
• Caliri AW , TommasiS , BesaratiniaA. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat. Res. Rev. Mutat. Res.787, 108365 (2021).
   PubMed Web of Science ®Google Scholar
• Sun C , HanB , ZhaiYet al. Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradation. Free Radic. Biol. Med.180, 220–235 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang GH , KaiJY , ChenMMet al. Downregulation of XBP1 decreases serous ovarian cancer cell viability and enhances sensitivity to oxidative stress by increasing intracellular ROS levels. Oncol. Lett.18(4), 4194–4202 (2019).
   PubMed Web of Science ®Google Scholar
• Liu N , PanT. N6-methyladenosine-encoded epitranscriptomics. Nat. Struct. Mol. Biol.23(2), 98–102 (2016).
   PubMed Web of Science ®Google Scholar
• Deng X , SuR , WengH , HuangH , LiZ , ChenJ. RNA n(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res.28(5), 507–517 (2018).
   PubMed Web of Science ®Google Scholar
• Liu T , WeiQ , JinJet al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res.48(7), 3816–3831 (2020).
   PubMed Web of Science ®Google Scholar
• Chen Y , MiaoL , LinH , ZhuoZ , HeJ. The role of m6A modification in pediatric cancer. Biochim. Biophys. Acta Rev. Cancer1877(2), 188691 (2022).
   PubMed Web of Science ®Google Scholar
• He J , YuanL , LinHet al. Genetic variants in m(6)A modification core genes are associated with glioma risk in Chinese children. Mol. Ther. Oncolytics20, 199–208 (2021).
   PubMed Web of Science ®Google Scholar
• Qu F , TsegayPS , LiuY. N(6)-methyladenosine, DNA repair, and genome stability. Front. Mol. Biosci.8, 645823 (2021).
   PubMed Web of Science ®Google Scholar
• Cai Y , WuG , PengBet al. Expression and molecular profiles of the AlkB family in ovarian serous carcinoma. Aging (Albany NY)13(7), 9679–9692 (2021).
   PubMedGoogle Scholar
• Wu M , ShangX , SunY , WuJ , LiuG. Integrated analysis of lymphocyte infiltration-associated lncRNA for ovarian cancer via TCGA, GTEx and GEO datasets. PeerJ8, e8961 (2020).
   PubMed Web of Science ®Google Scholar
• Tang R , ZhangY , LiangCet al. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. PeerJ8, e9602 (2020).
   PubMed Web of Science ®Google Scholar
• Ye W , LuoC , LiuF , LiuZ , ChenF. CD96 correlates with immune infiltration and impacts patient prognosis: a pan-cancer analysis. Front. Oncol.11, 634617 (2021).
   PubMedGoogle Scholar
• Lex A , GehlenborgN , StrobeltH , VuillemotR , PfisterH. UpSet: visualization of intersecting sets. IEEE Trans. Vis. Comput. Graph.20(12), 1983–1992 (2014).
   PubMed Web of Science ®Google Scholar
• Han B , JiangW , CuiPet al. Microglial PGC-1alpha protects against ischemic brain injury by suppressing neuroinflammation. Genome Med.13(1), 47 (2021).
   PubMed Web of Science ®Google Scholar
• Li Q , RenCC , ChenYNet al. A risk score model incorporating three m6A RNA methylation regulators and a related network of miRNAs-m6A regulators – m6A target genes to predict the prognosis of patients with ovarian cancer. Front. Cell Dev. Biol.9, 703969 (2021).
   PubMed Web of Science ®Google Scholar
• Guo J , ZhengJ , ZhangH , TongJ. RNA m6A methylation regulators in ovarian cancer. Cancer Cell Int.21(1), 609 (2021).
   PubMed Web of Science ®Google Scholar
• Ding DN , XieLZ , ShenYet al. Insights into the role of oxidative stress in ovarian cancer. Oxid. Med. Cell Longev.2021, 8388258 (2021).
   PubMed Web of Science ®Google Scholar
• Zhuang C , ZhuangC , LuoXet al. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1alpha signalling axis. J. Cell. Mol. Med.23(3), 2163–2173 (2019).
   PubMed Web of Science ®Google Scholar
• Ma Z , LiQ , LiuP , DongW , ZuoY. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell Biol. Int.44(12), 2524–2531 (2020).
   PubMed Web of Science ®Google Scholar
• Chen XY , ZhangJ , ZhuJS. The role of m(6)A RNA methylation in human cancer. Mol. Cancer18(1), 103 (2019).
   PubMed Web of Science ®Google Scholar
• Chang LL , XuXQ , LiuXLet al. Emerging role of m6A methylation modification in ovarian cancer. Cancer Cell Int.21(1), 663 (2021).
   PubMed Web of Science ®Google Scholar
• Gu J , BiF. Significance of n6-methyladenosine rNA methylation regulators in immune infiltrates of ovarian cancer. Front. Genet.12, 671179 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang C , LiuJ , GuoHet al. m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer. Bioengineered12(1), 3159–3176 (2021).
   PubMed Web of Science ®Google Scholar
• Ruan DY , LiT , WangYNet al. FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis. Oncogene40(33), 5168–5181 (2021).
   PubMed Web of Science ®Google Scholar
• Huang H , WangY , KandpalMet al. FTO-dependent n (6)-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res.80(16), 3200–3214 (2020).
   PubMed Web of Science ®Google Scholar
• Xie JW , HuangXB , ChenQYet al. m(6)a modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling. Mol. Cancer19(1), 114 (2020).
   PubMed Web of Science ®Google Scholar
• Ghazi T , NagiahS , ChuturgoonAA. Fusaric acid decreases p53 expression by altering promoter methylation and m6A RNA methylation in human hepatocellular carcinoma (HepG2) cells. Epigenetics16(1), 79–91 (2021).
   PubMed Web of Science ®Google Scholar
• Guo JY , WangXQ , SunLF. MicroRNA-488 inhibits ovarian cancer cell metastasis through regulating CCNG1 and p53 expression. Eur. Rev. Med. Pharmacol. Sci.24(6), 2902–2910 (2020).
   PubMed Web of Science ®Google Scholar
• Ramraj SK , ElayapillaiSP , PelikanRCet al. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int. J. Cancer147(4), 1086–1097 (2020).
   PubMed Web of Science ®Google Scholar